Aslan Pharmaceuticals Limited – American Depositar (NASDAQ:ASLN) Short Interest Decreased By 90%

November 10, 2018 - By Adrian Mccoy

The stock of Aslan Pharmaceuticals Limited – American Depositar (NASDAQ:ASLN) registered a decrease of 90% in short interest. ASLN’s total short interest was 200 shares in November as published by FINRA. Its down 90% from 2,000 shares, reported previously.

The stock increased 8.77% or $0.5 during the last trading session, reaching $6.2. About 250 shares traded. ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) has 0.00% since November 10, 2017 and is . It has underperformed by 15.62% the S&P500.

ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, develops therapeutics for the treatment cancer in Asia, the United States, Europe, and internationally. The company has market cap of $186.28 million. The company's product pipeline includes Varlitinib, a novel agent, which has completed Phase II studies in gastric and breast cancer, and entered into pivotal studies for biliary tract cancer; ASLAN002, a potent cMET and Recepteur d'Origine Nantais inhibitor that is in Phase II development for the treatment of gastric and breast cancer; and ASLAN003, a novel DHODH inhibitor, which is in Phase I clinical trials to treat acute myeloid leukemia and solid tumors. It currently has negative earnings. It is also developing ASLAN004, a monoclonal IL4/IL13 antibody that is under preclinical development for asthma and other tumor types; and ASLAN005, a monoclonal antibody, which is under preclinical development for RON, an immune checkpoint inhibitor.

More notable recent ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) news were published by: Nasdaq.com which released: “ASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic Dermatitis” on October 17, 2018, also Globenewswire.com with their article: “New Data Presented on ASLAN’s varlitinib at ESMO Show Promising Results in Heavily Pre-Treated BTC and CRC …” published on October 22, 2018, Seekingalpha.com published: “Key events next week – healthcare” on October 12, 2018. More interesting news about ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) were released by: Benzinga.com and their article: “Benzinga’s Week Ahead: Can Facebook, Apple Earnings Rescue The Stock Market?” published on October 29, 2018 as well as Nasdaq.com‘s news article titled: “ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting” with publication date: November 01, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>